



PATENT PORTFOLIO GROWS WITH GRANTING OF EUROPEAN PATENT

OBJ Limited (ASX: OBJ) today announced that it had received notice from the European Patent office of the granting of European Patent EP1694408 protecting the Company's powered magnetic delivery technology, known as Dermaportation.

The Company previously announced in December 2012 that this patent had been allowed and that the full granting of that Patent in Europe was subject to translation and filing in each of the member countries. This process is now complete and the Patent titled *Apparatus for the Facilitating Transdermal Delivery of Therapeutic Substances* is now in full effect.

Dermaportation was the first of the Company's three platform drug delivery technologies now being utilised across various international collaborations, partnerships and product development programs.

Dermaportation employs a micro-processor controlled magnetic enhancement system that has sufficient computing power to provide a number of additional consumer-focused value-added capabilities such as web programmability, smart-phone connectivity and personalised treatments. These capabilities have been incorporated into the **e-Skin**[®] product platform.

e-Skin[®] was the subject of a Collaboration Development Agreement with one of the world's largest multi-national cosmetic and fragrance companies announced to shareholders on 25 February 2013. The granting of the European Patent, in addition to the already granted US Patent, further strengthens the commercial value of the powered drug delivery technology.


For more information:

Mr Glyn Denison	Director	Telephone	+618 9443 3011
		Email	info@obj.com.au
		Web	www.obj.com.au

- ENDS -

OBJ Limited

leaders in magnetic micro-array drug delivery



About OBJ:

OBJ develops proprietary magnetic micro-array drug delivery and product enhancement technologies for the pharmaceutical, healthcare and consumer goods sectors.

OBJ partners companies in the design and development of next generation products using physical science rather than chemistry to provide new levels of product performance without the cost of reformulation or new ingredient approvals.

OBJ offers a portfolio of proprietary technologies and supports partners by providing IP-protected market exclusivity, expertise in magnetic array design, feasibility and efficacy and claims testing, engineering and production.

About OBJ's Technologies

OBJ has developed a platform of physical enhancement technologies based on low-cost magnetic micro-arrays that influence the movement and penetration of drugs, active ingredients and formulations at the molecular level.

Complex 3-D array and moving magnetic fields have the ability to repulse certain molecules to enhance diffusion and to alter the permeability of certain biological and non-biological targets.

OBJ develops low cost micro-array film technology that utilises diamagnetic repulsion, induced permeation and energy redirection to offer a new way of managing the speed, depth of penetration and delivery of active ingredients in a wide range of pharmaceutical and consumer products.

Forward-looking Statements

This announcement contains certain "forward-looking statements" concerning OBJ. Where OBJ expresses or implies an expectation or belief as to future events or results, such expectation or belief is expressed in good faith and believed to have a reasonable basis.

Forward-looking statements provided in this announcement are based on assumptions and contingencies which are subject to change without notice. Such forward-looking statements including statements regarding intentions, planned events and potential results are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance.

There can be no assurance that actual outcomes will not differ materially from these forward-looking statements, and there are risks associated with OBJ and the industry which may affect the accuracy of the forward-looking statements. OBJ does not undertake any obligation to release publicly any revisions to any forward looking statement to reflect events or circumstances after the date of this announcement or to reflect the occurrence of unanticipated events, except as may be required under applicable securities laws.

ABN 72 056 482 636

284 Oxford Street, Leederville 6007 Perth, Western Australia

Telephone +61 8 9443 3011 Facsimile +61 8 9443 9960

www.obj.com.au

For personal use only